Vivanza Biosci, a company in the Pharmaceuticals industry, reported revenue of ₹11 crore and net profit of ₹0.14 crore for the September 2026 quarter.
Vivanza Biosci. (BSE: VIVANZA) closed at ₹1.66 on 20 Nov 2026, down 22.4% over the past year. Its market capitalisation is ₹7 crore and it trades at 166.0 times earnings.
Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.